In a phase I clinical trial, the monoclonal antibody LFA102, a humanized neutralizing monoclonal antibody directed against the extracellular domain of PRLR, was tested in patients with advanced BC (10), which had previously caused tumor shrinkage in an in vivo model of BC (11). Here, PRLR is linked to neoplasm.